Physician profile

John C Abdou

Radiation Oncology · Rome, GA

NPI 1194885434

$5,695.78

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$370.55

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novocure INC. $5,346.59 2019-2024 Optune
Siemens Medical Solutions USA, INC. $173.28 2024 Truebeam
Varian Medical Systems, INC. $55.74 2019-2020
Taiho Oncology, INC. $45.69 2020-2021
Abbvie INC. $17.37 2021
Brainlab, INC. $15.90 2019
Intuitive Surgical, INC. $15.65 2024
Tactile Systems Technology INC $13.65 2021
Puma Biotechnology, INC. $11.91 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John C Abdou

$5,695.78

in general payments reported 2019-2025

Years
2019-2024
Top company
Novocure INC.

https://glasscript.com/doctor/280666/john-c-abdou

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.